メタ情報
| meta description平均長 | 26 |
|---|
| OGPありページ数 | 0 |
|---|
| Twitterカードありページ数 | 0 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 84 |
|---|
| ページあたり内部リンク平均 | 74.85 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| directors | 1 |
| auditors | 1 |
| Medicine | 0.995171 |
| Ltd | 0.904762 |
| Present | 0.857143 |
| cells | 0.793297 |
| Regeneration | 0.784654 |
| Inducing | 0.784654 |
| our | 0.784054 |
| Osaka | 0.761905 |
| Redasemtide | 0.732021 |
| Oct | 0.714286 |
| University | 0.714286 |
| stem | 0.705153 |
| has | 0.633274 |
| Director | 0.585617 |
| auditing | 0.571429 |
| external | 0.571429 |
| StemRIM | 0.562827 |
| patients | 0.562827 |
| research | 0.537244 |
| medicine | 0.528864 |
| system | 0.52381 |
| Inc | 0.52381 |
| External | 0.52381 |
| audits | 0.52381 |
| diseases | 0.506828 |
| President | 0.47619 |
| Apr | 0.47619 |
| corporate | 0.47619 |
| internal | 0.47619 |
| regeneration | 0.460494 |
| tissue | 0.460494 |
| epidermolysis | 0.439212 |
| bullosa | 0.439212 |
| new | 0.434911 |
| clinical | 0.409328 |
| epidermal | 0.380952 |
| protein | 0.380952 |
| Sep | 0.380952 |
| School | 0.380952 |
| Japan | 0.380952 |
| Auditor | 0.380952 |
| Company | 0.380952 |
| management | 0.380952 |
| phase | 0.380952 |
| trial | 0.380952 |
| have | 0.374612 |
| skin | 0.36601 |
| 再生誘導医薬 | 0.362921 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| Inducing | Regeneration | 4.519557 | 163 |
| Inducing | Medicine | 4.186161 | 161 |
| cells | stem | 3.767287 | 115 |
| bullosa | epidermolysis | 3.494628 | 48 |
| Medicine | Regeneration | 3.457995 | 131 |
| 再生誘導 | 再生誘導医学 | 3.151578 | 39 |
| Osaka | University | 3.111546 | 49 |
| 再生誘導医学 | 再生誘導医療 | 3.027816 | 26 |
| 相試験 | 開始 | 3.000988 | 26 |
| Graduate | School | 2.969805 | 28 |
| initiated | investigator | 2.935311 | 24 |
| HMGB1 | protein | 2.802845 | 27 |
| initiated | phase | 2.752522 | 24 |
| clinical | trial | 2.690704 | 32 |
| clinical | phase | 2.626545 | 31 |
| basement | membrane | 2.602119 | 16 |
| 独立行政法人 | 科学技術振興機構 | 2.597544 | 17 |
| Inc | StemRIM | 2.587132 | 41 |
| 再生誘導 | 再生誘導医療 | 2.586801 | 26 |
| Redasemtide | trial | 2.499452 | 32 |
| phase | trial | 2.48953 | 23 |
| regeneration | tissue | 2.468344 | 41 |
| diseases | intractable | 2.396303 | 36 |
| Daiwa | Securities | 2.392164 | 16 |
| の優位性 | 将来性 | 2.366187 | 12 |
| 将来性 | 論文 | 2.366187 | 12 |
| 学術発表 | 論文 | 2.366187 | 12 |
| bio | venture | 2.366187 | 12 |
| Adaptable | STEP | 2.366187 | 12 |
| Adaptable | Seamless | 2.366187 | 12 |
| Target | driven | 2.366187 | 12 |
| JST | 科学技術振興機構 | 2.346478 | 17 |
| Oct | Present | 2.340981 | 36 |
| はステムリムの登録商標です | 再生誘導医療 | 2.316956 | 13 |
| Inc | Oct | 2.292766 | 30 |
| dystrophic | epidermolysis | 2.277782 | 20 |
| 再生誘導医学 | 再生誘導医薬 | 2.277485 | 39 |
| auditing | committee | 2.26672 | 19 |
| 再生誘導 | 再生誘導医薬 | 2.264518 | 52 |
| Bio | Saito | 2.262528 | 13 |
| Bank | Sumitomo | 2.246018 | 14 |
| Chief | Scientific | 2.238063 | 12 |
| immune | rejection | 2.238063 | 12 |
| Bio | Incubator | 2.238063 | 12 |
| Program | Transfer | 2.238063 | 12 |
| investigator | phase | 2.224329 | 18 |
| cerebral | infarction | 2.195615 | 12 |
| Auditor | External | 2.195548 | 21 |
| functional | regeneration | 2.177437 | 27 |
| Received | grant | 2.169607 | 15 |
被リンク情報
このデータの閲覧には会員登録が必要になります。会員登録